SARS-CoV-2 Screening

The Vienna Covid-19 Detection Initiative (VCDI) is a collaborative, inter-institutional effort to combat the SARS-CoV-2 coronavirus. The initiative of research institutes at the Vienna BioCenter and the University of Vienna has repurposed existing resources and expertise, and invested in new infrastructure to develop capacities for detecting SARS-CoV-2.

The VCDI and its stakeholders promote a strategy for frequent, large-scale population screening to avoid damage caused by uncontrolled spreading of the virus through asymptomatic individuals. To this end, VCDI scientists are committed to developing novel, faster and cheaper approaches to detect SARS-CoV-2.

The initiative freely disseminates its know-how, operating procedures and latest developments. The VCDI is supported by the University of Vienna (Max Perutz Laboratories, Division of Microbial Ecology DOME), the Research Institute of Molecular Pathology IMP (Boehringer Ingelheim), the Institute of Molecular Biotechnology IMBA and Gregor Mendel Institute of Molecular Plant Biology GMI (both Austrian Academy of Sciences); and funded by a grant from the COVID-19 Rapid Response Call of the Vienna Science and Technology Fund (WWTF).



Prevalence of RT-qPCR-detected SARS-CoV-2 infection at schools: First results from the Austrian School-SARS-CoV-2 prospective cohort study. Willeit P, Krause R, Lamprecht B, Berghold A, Hanson B, Stelzl E, Stoiber H, Zuber J, Heinen R, Köhler A, Bernhard D, Borena W, Doppler C, von Laer D, Schmidt H, Pröll J, Steinmetz I, Wagner M. Lancet Reg Health Eur. 2021 5:100086